Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations : 2019-2021
© 2023. The Author(s)..
INTRODUCTION: In 2018, Anavip became available for the treatment of rattlesnake envenomations in the USA. No comparisons between the treatment characteristics of patients have been made since Anavip and CroFab have both been widely available. The objective of this study was to compare the number of antivenom vials administered of CroFab and Anavip during the treatment of rattlesnake envenomations in the USA.
METHODS: This was a secondary analysis of rattlesnake envenomations utilizing the North American Snakebite Registry (NASBR) from 2019 through 2021. Frequencies and proportions were used to summarize demographics and baseline clinical characteristics. The primary outcome was total antivenom vials administered during treatment. Secondary outcomes included the number antivenom administration events, total treatment time, and hospital length of stay.
RESULTS: Two hundred ninety-one rattlesnake envenomations were analyzed; most occurred in the Western USA (n = 279, 96 %). One hundred one patients (35%) received only CroFab, 110 (38%) received Anavip only, and 80 (27%) received both products. The median number of vials used was 10 for CroFab, 18 for Anavip, and 20 for both antivenoms. More than one antivenom administration was necessary in thirty-nine (39%) patients that received only CroFab and 76 (69%) patients that received Anavip only. The median total treatment time was 5.5 hours for CroFab, 6.5 for Anavip, and 15.5 hours when both antivenoms were administered. All antivenom groups had a median hospital length of stay of 2 days.
CONCLUSIONS: Rattlesnake envenomated patients in the Western USA treated with CroFab had fewer antivenom vials and fewer antivenom administrations compared to patients treated with Anavip.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of medical toxicology : official journal of the American College of Medical Toxicology - 19(2023), 3 vom: 28. Juli, Seite 248-254 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brandehoff, Nicklaus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
92VV7G83ED |
|---|
| Anmerkungen: |
Date Completed 28.06.2023 Date Revised 01.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13181-023-00941-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356190498 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356190498 | ||
| 003 | DE-627 | ||
| 005 | 20231226065933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13181-023-00941-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356190498 | ||
| 035 | |a (NLM)37115482 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brandehoff, Nicklaus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations |b 2019-2021 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: In 2018, Anavip became available for the treatment of rattlesnake envenomations in the USA. No comparisons between the treatment characteristics of patients have been made since Anavip and CroFab have both been widely available. The objective of this study was to compare the number of antivenom vials administered of CroFab and Anavip during the treatment of rattlesnake envenomations in the USA | ||
| 520 | |a METHODS: This was a secondary analysis of rattlesnake envenomations utilizing the North American Snakebite Registry (NASBR) from 2019 through 2021. Frequencies and proportions were used to summarize demographics and baseline clinical characteristics. The primary outcome was total antivenom vials administered during treatment. Secondary outcomes included the number antivenom administration events, total treatment time, and hospital length of stay | ||
| 520 | |a RESULTS: Two hundred ninety-one rattlesnake envenomations were analyzed; most occurred in the Western USA (n = 279, 96 %). One hundred one patients (35%) received only CroFab, 110 (38%) received Anavip only, and 80 (27%) received both products. The median number of vials used was 10 for CroFab, 18 for Anavip, and 20 for both antivenoms. More than one antivenom administration was necessary in thirty-nine (39%) patients that received only CroFab and 76 (69%) patients that received Anavip only. The median total treatment time was 5.5 hours for CroFab, 6.5 for Anavip, and 15.5 hours when both antivenoms were administered. All antivenom groups had a median hospital length of stay of 2 days | ||
| 520 | |a CONCLUSIONS: Rattlesnake envenomated patients in the Western USA treated with CroFab had fewer antivenom vials and fewer antivenom administrations compared to patients treated with Anavip | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anavip | |
| 650 | 4 | |a Antivenom | |
| 650 | 4 | |a CroFab | |
| 650 | 4 | |a Fab | |
| 650 | 4 | |a Fab2 | |
| 650 | 4 | |a Rattlesnake | |
| 650 | 7 | |a anavip |2 NLM | |
| 650 | 7 | |a 92VV7G83ED |2 NLM | |
| 650 | 7 | |a Crotalidae Polyvalent immune Fab |2 NLM | |
| 650 | 7 | |a Antivenins |2 NLM | |
| 650 | 7 | |a Immunoglobulin Fab Fragments |2 NLM | |
| 700 | 1 | |a Dalton, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Daugherty, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Dart, Richard C |e verfasserin |4 aut | |
| 700 | 1 | |a Monte, Andrew A |e verfasserin |4 aut | |
| 700 | 0 | |a ToxIC Snakebite Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical toxicology : official journal of the American College of Medical Toxicology |d 2005 |g 19(2023), 3 vom: 28. Juli, Seite 248-254 |w (DE-627)NLM175675902 |x 1937-6995 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:3 |g day:28 |g month:07 |g pages:248-254 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13181-023-00941-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 3 |b 28 |c 07 |h 248-254 | ||